20 articles
A randomized phase 2 trial finds CM313 achieves 83% response rate vs 20% placebo in treatment-resistant immune thrombocytopenia.
Researchers develop standardized lung washing procedure that rapidly improves breathing and quality of life in patients with rare disease.
A landmark 48-RCT Cochrane review finds high-certainty evidence that convalescent plasma does not reduce death in moderate-to-severe COVID-19.
A major review outlines how targeted hematologic therapies are transforming outcomes in MGRS, a rare but serious cause of kidney injury.
A completed Phase 3 trial tests placental MSC secretome injections against placebo in 60 GvHD patients at an Iranian hospital.
A rigorous 2025 review finds no approved AMR therapy and reassesses all current evidence, spotlighting CD38 antibodies and complement inhibition.
A phase 1/2 trial finds low-dose oral NMN safely raises platelet counts in steroid-refractory ITP via a novel immunometabolic mechanism.
Scientists identify key mechanism that determines why some immune thrombocytopenia patients maintain remission after stopping treatment.
A Phase 4 trial compares two antiretroviral strategies in treatment-naive HIV patients with dangerously low CD4 counts below 100.
Daratumumab monotherapy showed promising results in treating refractory lupus nephritis by reducing inflammation and fibrosis.
A 2025 meta-analysis of 11 RCTs finds Tฮฑ1 reduces 28-day sepsis mortality overall, but high-quality trial data tells a more nuanced story.
A Phase 4 trial tests whether simplifying HIV treatment to two drugs worsens hidden viral replication and immune dysfunction.
New research shows how targeted interleukin-2 treatment can restore regulatory T cells and reduce muscle inflammation in autoimmune conditions.
A completed RCT tests whether 1-hour pathogen detection paired with antimicrobial stewardship slashes broad-spectrum antibiotic days in HAP patients.
Scientists discover how blocking CD40-CD40L pathway reduces dangerous clotting in antiphospholipid syndrome patients.
Engineered immune cells offer new hope for treating kidney diseases that resist standard therapies, potentially improving long-term health outcomes.
New research reveals why giving multiple doses of a promising type 1 diabetes treatment doesn't improve outcomes beyond a single course.
A completed Phase 3 trial evaluated whether the anti-TNF biologic infliximab safely and effectively treats plaque psoriasis.
Delphi study of 166 Italian neurologists establishes guidelines for individualized MS therapy based on patient needs and drug characteristics.
A randomized trial shows prophylactic obinutuzumab dramatically reduces steroid-requiring cGVHD after bone marrow transplant.
